清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

PB2398: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASIA IN 2 CENTERS OF BOGOTÁ – COLOMBIA: THE LARGEST CASE SERIES IN LATIN AMERICA

医学 免疫分型 内科学 淋巴瘤 骨髓 外科 胃肠病学 免疫学 流式细胞术
作者
María Cynthia Fuentes-Lacouture,Leonardo Bautista-Toloza,Leonardo Enciso-Olivera,Alberto Mario Pereira,María Isabel Posada Arbeláez,Jaime Valdés,Humberto Martínez‐Cordero
出处
期刊:HemaSphere [Wolters Kluwer]
卷期号:7 (S3): e15684e2-e15684e2
标识
DOI:10.1097/01.hs9.0000976304.15684.e2
摘要

Topic: 20. Lymphoma Biology & Translational Research Background: Blastic Plasmacytoid Dendritic Cell neoplasia or BPDCN has an aggressive clinical behavior with a very poor prognosis and high mortality. It represents a proportion of only 0.44% of hematological malignancies. Diagnosis is based on the immunophenotype on bone marrow and skin lesions´ samples. Treatment varies between intensive treatments, monoclonal antibodies, and hematopoietic progenitor transplantation. We present the largest cohort of patients with BPDCN described to date in Latin American patients. Aims: To describe and analyze the demographic, clinical, and paraclinical characteristics of 8 patients treated in 2 reference centers in the country. Methods: Data of patients diagnosed with BPCDN between 2007 and 2023 was collected. Diagnosis was made with biopsy of skin lesions and bone marrow. After an adequate classification and diagnosis of the disease, 8 of 9 patients were included in the case series. Results: A total of 8 patients were diagnosed. Most of the patients were male (5:3), with a mean age of 62 years (20-85 years). All patients had dermatological lesions at diagnosis (figure 1). Half of the cases presented splenomegaly. Seven patients (87.5%) had bone marrow involvement. Of these, 100% had a positive immunophenotype for HLA DR+, CD4+, CD123+, and CD56, with heterogeneous positivity for CD117, and CD45. Regarding treatment, four patients (50%) received HyperCVAD, one patient cytarabine + idarubicin, one patient CHOP, and one patient 5-azacitidine + venetoclax. Four died from complications associated with disease progression or treatment complications. Three patients are still alive, of which one is still undergoing treatment. Overall survival was 9.8 months (range 3 weeks to 16 months). Only one patient (12.5%) underwent allogeneic stem cell transplantation (Table 1). Summary/Conclusion: Blastic plasmacytoid dendritic cell neoplasm is a rare entity, with small case series reported in the literature. It is a disease with a clinical aggressive behavior, which mostly affects the skin and bone marrow. Treatment is usually based on high-intensity chemotherapy. We recognize the need to create collaborative groups dedicated to strengthening knowledge around this disease to improve outcomes for patients around the world. - Patient Age Gender BM Involvement Skin Involvement BM immunophenotype Skin immunophenotype Treatment OS (months) 1 20 F Yes Yes HLA DR+, CD123+, CD56+, CD4 -/+, CD117- No data Cytarabine + Idarubicin (7 + 3) 14 2 85 M Yes Yes HLA DR+, CD123+, CD56+, CD4 -/+, CD117+, CD45+ No data CHOP 1 3 61 M Yes Yes HLA DR+, CD123+, CD56+, CD4 -/+, CD117+, CD45 -/+ No data HyperCVAD 6 4 81 M Yes Yes HLA DR+, CD123+, CD33 -/+, CD4+, CD45 -/+ CD4+, CD56+ Not received No data 5 50 F Yes Yes HLA DR+, CD123+, CD56+, CD4+, CD45 -/+ CD4+, CD56+ HyperCVAD + Allo SCT Not reached 6 56 M Yes Yes HLA DR+, CD123+, CD56+, CD4+, CD7+, CD45+ No data HyperCVAD 16 7 67 F Yes Yes HLA DR+, CD123+, CD56+, CD4+, CD45 -/+ CD4+, CD56+ HyperCVAD Not reached 8 82 M No Yes No involvement CD4+, CD56+, CD123 -/+, CD33 -/+ 5-Azacitidine + Venetoclax Not reached Table 1. Clinical characteristics, including treatment details of 8 patients with blastic plasmacytoid dendritic cell neoplasm treated in 2 reference centers in Bogotá D.C., Colombia. BM: Bone marrow, OS: overall survival; CHOP: cyclophosphamide, hydroxidaunorubicine, vincristine, prednisone; HyperCVAD: cyclophosphamide, vincristine, doxorubicine, dexamethasone, methotrexate, cytarabine.Figure 1. Dermatologic lesions of patients 6, 7 and 8 at diagnosis, respectively. Keywords: Plasma cells, Dendritic cell, Lymphoma, NK cell

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zyjsunye完成签到 ,获得积分10
3秒前
健康的忘幽完成签到,获得积分10
8秒前
12秒前
闪闪小凡完成签到,获得积分10
16秒前
小小菜完成签到 ,获得积分10
17秒前
白的肥发布了新的文献求助10
20秒前
Alice完成签到 ,获得积分10
31秒前
n01W97的应助被科研通管家采纳,获得20
33秒前
詹姆斯哈登完成签到,获得积分0
37秒前
stone完成签到 ,获得积分10
47秒前
我很好完成签到 ,获得积分10
1分钟前
清爽水之完成签到,获得积分10
1分钟前
tianshanfeihe完成签到 ,获得积分10
1分钟前
FashionBoy的应助被白的肥采纳,获得10
1分钟前
从容棉花糖完成签到,获得积分10
1分钟前
1分钟前
elsa622完成签到 ,获得积分10
1分钟前
1分钟前
白的肥发布了新的文献求助10
1分钟前
负责谷秋完成签到 ,获得积分10
1分钟前
白的肥完成签到,获得积分10
1分钟前
孤独剑完成签到 ,获得积分10
1分钟前
timesever完成签到,获得积分10
1分钟前
小新小新完成签到 ,获得积分10
1分钟前
amiee发布了新的文献求助10
1分钟前
义气绍辉完成签到,获得积分10
1分钟前
kylin完成签到 ,获得积分10
2分钟前
沉静的愫完成签到,获得积分10
2分钟前
李爱国的应助被段宏涛采纳,获得10
2分钟前
放手一搏完成签到,获得积分10
2分钟前
今后的应助被科研通管家采纳,获得10
2分钟前
稳重傲柔完成签到,获得积分10
2分钟前
mzhang2完成签到 ,获得积分10
2分钟前
whitepiece完成签到,获得积分0
2分钟前
等待念之完成签到,获得积分10
2分钟前
水星逃逸完成签到 ,获得积分10
3分钟前
Alger完成签到,获得积分10
3分钟前
漂亮傲云完成签到,获得积分10
3分钟前
zzzy完成签到 ,获得积分10
3分钟前
ZZZ完成签到 ,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185496
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834498
捐赠科研通 7783092
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558949
邀请新用户注册赠送积分活动 2481346